Evenity (Romosozumab) Cost in Missouri 2026: Insurance, Medicaid, and Savings Options

Romosozumab-aqqg, marketed as Evenity, is a monoclonal antibody that works by inhibiting sclerostin and is administered via monthly subcutaneous injection. The FDA has approved this medication for treating osteoporosis in postmenopausal women who face a high fracture risk, with the approved course limited to 12 months. Unlike denosumab (Prolia), teriparatide (Forteo), and bisphosphonate drugs, romosozumab belongs to a distinct pharmacologic class, though patients in Missouri commonly evaluate costs among all four options when deciding on treatment.

Direct answer: Evenity's manufacturer list price (wholesale acquisition cost) has been widely reported around $1,825 per monthly dose, which would put a full 12-dose course near $21,900 before insurance, though exact current pricing should be confirmed with Amgen or a Missouri specialty pharmacy since list prices change and this figure is not drawn from a primary pricing filing verified for this article. Missouri Medicaid (MO HealthNet) does not appear to cover Evenity for osteoporosis as of this review, commercial insurers generally require prior authorization, and the manufacturer's copay program can reduce out-of-pocket costs substantially for eligible commercially insured patients. Every dollar figure below should be reverified before a patient makes a treatment decision.

What Evenity typically costs before insurance

Romosozumab is supplied as two prefilled syringes that are administered together as a single 210 mg dose. The FDA label describes the dosing regimen and the boxed cardiovascular warning discussed below (FDA prescribing information, accessdata.fda.gov). Reported wholesale pricing for a monthly dose has been in the range of roughly $1,800, which over a full 12-month course would total in the low twenty-thousands of dollars. This article does not have a verified, dated pricing source specific to Missouri pharmacies, so treat any dollar figure here as a planning estimate rather than a quote you can rely on for a specific pharmacy.

Administration is typically done in a provider's office or infusion center, which can add a separate facility or administration fee on top of the drug cost. Because no generic or biosimilar romosozumab exists, price variation between brand-name suppliers is expected to be small, and most of the real cost difference for a Missouri patient will come from insurance tier placement and whether copay assistance applies, not from shopping between pharmacies.

Does Missouri Medicaid cover Evenity?

Based on available formulary information, MO HealthNet (Missouri Medicaid) does not cover Evenity for osteoporosis; any coverage that exists appears limited to unrelated indications. This is a state-specific and potentially time-sensitive policy detail, and it should be confirmed directly with MO HealthNet or the patient's Medicaid managed care plan before assuming it is still accurate.

Patients on Missouri Medicaid who need romosozumab can ask their prescriber to submit a formulary exception request documenting prior treatment failure with other osteoporosis therapies and fracture history. Approval is not guaranteed, and outcomes vary by case. A large randomized trial comparing romosozumab to alendronate in postmenopausal women (the ARCH trial) found a reduction in clinical fractures with romosozumab-then-alendronate compared with alendronate alone; the exact magnitude of that reduction should be verified against the published trial report rather than repeated from memory, since this article does not have a confirmed primary-source citation for the specific percentage.

Patients who are dual-eligible for Medicare and Medicaid may have a more workable path through Medicare Part B, which covers physician-administered osteoporosis injections under separate criteria, typically requiring documentation of fracture risk and prior therapy.

Will commercial insurance cover it, and what will it take?

Major commercial insurers operating in Missouri generally place Evenity on a specialty tier and require prior authorization. Typical criteria reported across payers include a confirmed osteoporosis diagnosis (by bone density T-score or fragility fracture history), documented failure of or intolerance to at least one bisphosphonate, and prescribing by a specialist such as an endocrinologist or rheumatologist. Some plans add a step-therapy requirement involving denosumab or teriparatide first. Because prior authorization criteria change and vary by specific plan, confirm the current requirement with the patient's insurer rather than assuming any list here is complete.

Professional guidelines from endocrine specialty organizations have supported romosozumab or another bone-forming (anabolic) agent as a reasonable first-line option for patients at very high fracture risk, defined by factors such as a recent fracture, very low bone density, or an elevated fracture-risk score. Citing the current version of the relevant specialty guideline, rather than a specific percentage or year that cannot be verified here, is the safer approach for a prior authorization appeal.

Out-of-pocket costs for commercially insured Missouri patients can range widely, from $0 with manufacturer copay assistance to several hundred dollars per injection under coinsurance-based specialty tiers, depending on plan design.

How the manufacturer copay program works

Amgen and UCB, the companies that market Evenity, operate a copay assistance program for eligible commercially insured patients. Programs of this type typically reduce out-of-pocket cost toward $0 up to an annual maximum, and they generally exclude patients enrolled in Medicare, Medicaid, Tricare, or other government insurance. Program terms, income rules, and annual caps change periodically, so a patient should confirm current terms directly with the manufacturer or the enrollment materials at the time of prescribing rather than relying on a cached description.

Patients whose plan does not fully cover Evenity, and who do not qualify for the manufacturer card because they have government insurance, may want to ask their care team about independent patient assistance foundations that support osteoporosis treatment costs. Availability and funding at these foundations change over time and are not guaranteed.

One practical pitfall: manufacturer copay cards generally cannot be used at 340B-covered pharmacies or combined with government insurance. Patients receiving care at a federally qualified health center should ask whether their dispensing pharmacy is 340B-designated before assuming the card will apply.

Verification checklist: what is stable versus what changes

Because this page mixes federal drug facts with state and payer details that shift over time, use this checklist to separate what a reader can trust as written from what must be reconfirmed before making a financial or treatment decision.

Stable facts, unlikely to change quickly (federal/clinical):

• Evenity (romosozumab-aqqg) is FDA-approved for osteoporosis in postmenopausal women at high fracture risk, given as a 210 mg monthly subcutaneous injection for 12 months. Source: FDA prescribing information.
• The FDA label carries a boxed warning against starting romosozumab in patients with a myocardial infarction or stroke within the prior year. Source: FDA prescribing information.
• Repeat courses of romosozumab beyond the initial 12 months are not FDA-approved and are not supported by large controlled trials.
• Compounded versions of romosozumab are not FDA-approved products and have not undergone the agency's review for safety, purity, and potency. Source: FDA compounding guidance.

Facts that must be reverified before relying on them (state, payer, pharmacy, or cash price):

• The current WAC or cash price per dose at any specific Missouri pharmacy.
• Whether MO HealthNet's Evenity coverage policy has changed since this review date.
• The specific prior authorization or step-therapy criteria at a given commercial plan (these are plan-year specific).
• The current annual maximum benefit and eligibility rules for the manufacturer copay card.
• Current Medicare Part B deductible and coinsurance amounts for the relevant benefit year.
• Whether a specific 503A pharmacy in Missouri currently compounds romosozumab and under what documentation requirements.

If a number in this article does not match what a patient's pharmacy, insurer, or MO HealthNet caseworker tells them, trust the direct, current source over this page.

Compounded romosozumab through 503A pharmacies

Missouri pharmacy law permits 503A compounding of prescription products, including some biologic-adjacent preparations, under a patient-specific prescription and board oversight. A critical distinction applies here: compounded romosozumab is not an FDA-approved product. It has not gone through the manufacturing quality control, bioequivalence testing, or stability studies that the commercial Evenity product has undergone. The FDA has published guidance addressing the risks of compounding complex biologic products outside an approved biologics license application (FDA compounding guidance, fda.gov).

In practice, most Missouri endocrinologists and rheumatologists prescribe the commercial product rather than a compounded version, because the standard 210 mg dose covers the vast majority of patients and there is little clinical reason to seek an alternative preparation. Patients who are still considering a compounded product should ask the pharmacy about third-party potency testing, documented stability data, and whether the prescribing physician is prepared to monitor outcomes closely given the absence of FDA review for that specific preparation.

Telehealth prescribing in Missouri

Missouri permits telehealth prescribing of Evenity. A Missouri-licensed physician can review bone density results and fracture history by video visit and issue a prescription without an in-person visit for that consultation. Administration is a separate matter: romosozumab is given as an injection, and while a trained patient or caregiver could theoretically administer it, most insurance plans and specialty pharmacies route the drug through a provider's office or infusion center for monthly administration.

A typical pathway looks like an initial telehealth consultation and prescription, followed by specialty pharmacy shipment to a local infusion site or provider office for the monthly injections, with follow-up bone density monitoring conducted by telehealth when appropriate. State telehealth reimbursement parity rules for commercial insurers exist in Missouri; confirm current requirements with the Missouri Department of Commerce and Insurance or the specific insurer, since statute citations and reimbursement rules can be updated.

How Evenity compares to other osteoporosis treatments on cost

For Missouri patients weighing cost against Evenity, other osteoporosis therapies are generally reported to cost substantially less per month, particularly generic oral bisphosphonates such as alendronate. Injectable options such as zoledronic acid (given annually) and denosumab (given twice yearly) fall at different price points, and teriparatide, an older anabolic option, has historically carried a price closer to Evenity's range. These figures move over time and by pharmacy, so treat any specific number as an estimate rather than a quote.

A large randomized trial (ARCH) compared 12 months of romosozumab followed by alendronate against alendronate alone and found a statistically significant reduction in clinical fractures favoring the romosozumab-first sequence over roughly three years of follow-up. A separate placebo-controlled trial (FRAME) found a reduction in new vertebral fractures with romosozumab compared with placebo at 12 months. This article does not carry a verified citation link for either trial's exact percentages; a clinician recommending romosozumab based on these results should confirm the current published figures directly rather than relying on a secondhand summary.

Cardiovascular safety and who should avoid this drug

Romosozumab's FDA label includes a boxed warning against initiation in patients with myocardial infarction or stroke within the past year (FDA prescribing information, accessdata.fda.gov). This warning stems from a cardiovascular imbalance detected when romosozumab was compared to alendronate in clinical trials, though debate continues in published research about whether the signal represents direct harm from romosozumab or instead demonstrates a cardioprotective benefit of alendronate, an interpretation that cannot be definitively resolved from trial data alone.

What is established: patients with a recent MI or stroke are contraindicated. What is plausible but not settled: whether romosozumab carries independent cardiovascular risk beyond this contraindicated group, versus the signal reflecting a comparator effect. What is not established here: a specific numeric event rate that this article can responsibly repeat without a verified citation. Missouri prescribers should document a cardiovascular risk-benefit discussion for patients with significant atherosclerotic risk factors before starting therapy, and patients with new chest pain, one-sided weakness, or stroke symptoms during treatment should seek emergency care immediately rather than waiting for a scheduled follow-up.

Getting coverage in place: a sequential approach

For commercial insurance, a workable order of operations is to have the prescriber submit prior authorization with bone density results, fracture history, and documentation of prior bisphosphonate use, appeal with reference to current specialty-society guidance if denied, and enroll in the manufacturer copay program in parallel so savings apply as soon as approval comes through.

For Medicare Part B, Evenity is billed as a physician-administered drug and is generally subject to the standard Part B deductible and 20% coinsurance once that deductible is met; confirm the current-year deductible and expected coinsurance dollar amount with Medicare.gov or the patient's plan, since these figures change annually.

For Missouri Medicaid, expect that a straightforward request may be denied, and plan for a documented exception request or a look at Medicare Part B eligibility if the patient is dual-eligible.

What happens after the 12-month course

Romosozumab is approved for a single 12-month course. Reported follow-up data indicate that bone density gains from romosozumab can begin to reverse within roughly a year of stopping treatment if no follow-on antiresorptive therapy is started. The standard practice pattern described in specialty guidance is to complete the 12 monthly injections and then transition to an antiresorptive agent, commonly denosumab or a bisphosphonate, to preserve the gains. Missouri patients should plan financially for this second phase of treatment from the outset, since it represents an ongoing cost even after the more expensive anabolic phase ends.

Repeat courses of romosozumab years later have been explored in smaller or open-label studies but are not FDA-approved and are not standard practice; a patient considering this should understand it as an off-label decision made individually with their prescriber.